NPS Pharmaceuticals, Inc.
550 Hills Drive
3rd Floor
Bedminster,
NJ 07921
Phone: 908-450-5300
Fax: 908-450-5351
Web Site: http://www.npsp.com
| NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of specialty therapeutics for gastrointestinal and endocrine disorders. The company is advancing two late-stage programs to restore or replace biological function, including GATTEX (teduglutide), which is in Phase 3 clinical development for parenteral dependent short bowel syndrome; and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) that is in Phase 3 clinical development as a hormone therapy for hypoparathyroidism. It complements its internal programs with strategic partnerships with Amgen, GlaxoSmithKline, Kyowa Kirin, and Nycomed. The company was founded in 1986 and is headquartered in Bedminster, New Jersey. |
|
| Key Statistics |
|
|
|
| |
Pay |
Exercised |
Dr. Francois Nader MD, MBA, 51
Chief Exec. Officer, Pres
|
$
729.00K |
$
0 |
Mr. Luke M. Beshar CPA, 51
Chief Financial Officer, Principal Accounting Officer and Sr. VP
|
$
461.00K |
$
0 |
Mr. Andrew Rackear JD, 55
Sr. VP of Legal Affairs, Sec. and Gen. Counsel
|
N/A
|
N/A |
Dr. Roger J. Garceau M.D., FAAP, 56
Chief Medical Officer and Sr. VP
|
$
8.00K |
$
0 |
Dr. Bo Joelsson M.D., Ph.D.,
Head of Clinical Research
|
N/A
|
N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
|
|
|
Help
Profile
